HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles In Vitro and In Vivo in a Murine Model of Experimental Vaginitis.

Abstract
Candida albicans is an important opportunistic pathogen causing various human infections that are often treated with azole antifungals. The U.S. CDC now regards developing candidal antifungal resistance as a threat, creating a need for new and more effective antifungal treatments. Iron is an essential nutrient for all living cells, and there is growing evidence that interference with iron homeostasis of C. albicans can improve its response to antifungals. This study was aimed at establishing whether withholding iron by currently used medical iron chelators and the novel chelator DIBI could restrict growth and also enhance the activity of azoles against clinical isolates of C. albicans DIBI, but not deferoxamine or deferiprone, inhibited the growth of C. albicans at relatively low concentrations in vitro, and this inhibition was reversed by iron addition. DIBI in combination with various azoles demonstrated stronger growth inhibition than the azoles alone and greatly prolonged the inhibition of cell multiplication. In addition, the administration of DIBI along with fluconazole (FLC) to mice inoculated with an FLC-sensitive isolate in a model of experimental C. albicans vaginitis showed a markedly improved clearance of infection. These results suggest that iron chelation by DIBI has the potential to enhance azole efficacy for the treatment of candidiasis.
AuthorsKimberley A Savage, Maria del Carmen Parquet, David S Allan, Ross J Davidson, Bruce E Holbein, Elizabeth A Lilly, Paul L Fidel Jr
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 62 Issue 8 (08 2018) ISSN: 1098-6596 [Electronic] United States
PMID29844048 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2018 American Society for Microbiology.
Chemical References
  • Antifungal Agents
  • Azoles
  • Deferiprone
  • Deferoxamine
Topics
  • Animals
  • Antifungal Agents (therapeutic use)
  • Azoles (therapeutic use)
  • Candida (drug effects, pathogenicity)
  • Candida albicans (drug effects, pathogenicity)
  • Deferiprone (therapeutic use)
  • Deferoxamine (therapeutic use)
  • Disease Models, Animal
  • Drug Resistance, Fungal
  • Drug Synergism
  • Female
  • Mice
  • Vaginitis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: